Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.

Hiroya Taniguchi,Kentaro Yamazaki,Toshiki Masuishi,Takeshi Kawakami,Yusuke Onozawa,Kazunori Honda,Shigenori Kadowaki,Yukiya Narita,Takahiro Tsushima,Satoshi Hamauchi,Akiko Todaka,Tomoya Yokota,Masashi Ando,Keita Mori,Hiromichi Shirasu,Hirofumi Yasui,Kei Muro

The oncologist（2023）

引用 0|浏览7

暂无评分

摘要

Biweekly trifluridine/tipiracil, irinotecan, and bevacizumab administration may have moderate antitumor activity with high risk of severe myelotoxicity in previously treated patients with metastatic colorectal cancer [UMIN Clinical Trials Registry (UMIN000019828) and Japan Registry of Clinical Trials (jRCTs041180028)].

查看译文

关键词

bevacizumab, chemotherapy, colorectal cancer, irinotecan, trifluridine, tipiracil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要